AbCellera Biologics Inc. Deferred Federal Income Tax Expense (Benefit)
AbCellera Biologics Inc. (ABCL) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-24
- AbCellera Biologics Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AbCellera Biologics Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $749.00K, a 83.45% decline from fiscal 2023.
- AbCellera Biologics Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $4.53M, a 94.92% increase from fiscal 2022.
- AbCellera Biologics Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $2.32M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 |
| 2024-12-31 | $749.00K 10-K · filed 2026-02-24 |
| 2023-12-31 | $4.53M 10-K · filed 2026-02-24 |
| 2022-12-31 | $2.32M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$1.34M 10-K · filed 2024-02-20 |
| 2020-12-31 | $2.46M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |